Haeri Seol

525 total citations
11 papers, 394 citations indexed

About

Haeri Seol is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Haeri Seol has authored 11 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 3 papers in Cardiology and Cardiovascular Medicine and 2 papers in Oncology. Recurrent topics in Haeri Seol's work include Muscle Physiology and Disorders (5 papers), Cardiomyopathy and Myosin Studies (3 papers) and Peptidase Inhibition and Analysis (2 papers). Haeri Seol is often cited by papers focused on Muscle Physiology and Disorders (5 papers), Cardiomyopathy and Myosin Studies (3 papers) and Peptidase Inhibition and Analysis (2 papers). Haeri Seol collaborates with scholars based in United States and Canada. Haeri Seol's co-authors include Kristy J. Brown, Eric P. Hoffman, Yetrib Hathout, Yetrib Hathout, Aiping Zhang, Dinesh K. Pillai, Heather Gordish‐Dressman, Jean K. Mah, Craig M. McDonald and Erik Henricson and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and Analytical Chemistry.

In The Last Decade

Haeri Seol

9 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haeri Seol United States 8 292 84 76 58 45 11 394
Jolanta Kordowska United States 12 407 1.4× 109 1.3× 48 0.6× 43 0.7× 14 0.3× 16 548
Clarence A. Dunn United States 8 534 1.8× 63 0.8× 57 0.8× 72 1.2× 9 0.2× 9 637
Monika Hiller Netherlands 9 325 1.1× 47 0.6× 54 0.7× 63 1.1× 6 0.1× 13 369
Shlomit Boguslavsky Canada 9 417 1.4× 173 2.1× 114 1.5× 24 0.4× 4 0.1× 9 559
Ivana Dabaj France 11 256 0.9× 41 0.5× 42 0.6× 49 0.8× 7 0.2× 27 386
Nandini V. L. Hayes United Kingdom 12 247 0.8× 87 1.0× 81 1.1× 26 0.4× 7 0.2× 23 351
Yuichi Kunori Japan 10 168 0.6× 33 0.4× 137 1.8× 21 0.4× 5 0.1× 12 484
Shinji Go Japan 12 417 1.4× 122 1.5× 109 1.4× 14 0.2× 7 0.2× 24 494
Penio Todorov United Kingdom 8 290 1.0× 59 0.7× 268 3.5× 24 0.4× 7 0.2× 8 597
Jonathan Bruno United States 8 222 0.8× 48 0.6× 35 0.5× 23 0.4× 6 0.1× 11 362

Countries citing papers authored by Haeri Seol

Since Specialization
Citations

This map shows the geographic impact of Haeri Seol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haeri Seol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haeri Seol more than expected).

Fields of papers citing papers by Haeri Seol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haeri Seol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haeri Seol. The network helps show where Haeri Seol may publish in the future.

Co-authorship network of co-authors of Haeri Seol

This figure shows the co-authorship network connecting the top 25 collaborators of Haeri Seol. A scholar is included among the top collaborators of Haeri Seol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haeri Seol. Haeri Seol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Zhong, Jieqiang, Ming Huang, Haibo Qiu, et al.. (2024). Simple endoglycosidase-assisted peptide mapping workflow for characterizing non-consensus n-glycosylation in therapeutic monoclonal antibodies. Journal of Pharmaceutical Sciences. 114(2). 1125–1132. 1 indexed citations
3.
Seol, Haeri, et al.. (2017). Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy. Pediatric Cardiology. 38(8). 1606–1612. 15 indexed citations
4.
Boca, Simina M., Michael A. Harris, Shruti Rao, et al.. (2016). Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS ONE. 11(4). e0153461–e0153461. 31 indexed citations
5.
Hathout, Yetrib, Laurie S. Conklin, Haeri Seol, et al.. (2016). Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Scientific Reports. 6(1). 31727–31727. 36 indexed citations
6.
Hathout, Yetrib, et al.. (2016). Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clinical Proteomics. 13(1). 9–9. 60 indexed citations
7.
Seol, Haeri, et al.. (2015). ELEVATED ST2 SERUM LEVELS A BIOMARKER FOR CARDIOMYOPATHY IN DUCHENNE MUSCULAR DYSTROPHY. Journal of the American College of Cardiology. 65(10). A997–A997.
8.
Hathout, Yetrib, Sree Rayavarapu, Aiping Zhang, et al.. (2014). Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Human Molecular Genetics. 23(24). 6458–6469. 94 indexed citations
9.
Brown, Kristy J., Haeri Seol, Dinesh K. Pillai, et al.. (2013). The human secretome atlas initiative: Implications in health and disease conditions. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1834(11). 2454–2461. 60 indexed citations
10.
Brown, Kristy J., Haeri Seol, Stéphanie Duguez, et al.. (2012). Advances in the proteomic investigation of the cell secretome. Expert Review of Proteomics. 9(3). 337–345. 87 indexed citations
11.
Chen, Huiling, Haeri Seol, Kristy J. Brown, et al.. (2012). Secretome Survey of Human Plexiform Neurofibroma Derived Schwann Cells Reveals a Secreted form of the RARRES1 Protein. International Journal of Molecular Sciences. 13(7). 9380–9399. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026